XML 44 R34.htm IDEA: XBRL DOCUMENT
v3.8.0.1

CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) - USD ($) $ / shares in Units, shares in Millions |  |  |  |  | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Aug. 29, 2017 | Jul. 06, 2016 | Jul. 07, 2014 | Feb. 13, 2014 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Dec. 31, 2016
Co-development and license agreement |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | $ 41,175,600 |  | $ 41,175,600 |  |
Research and development expense |  |  |  |  | 8,956,468 | $ 5,852,121 | 23,714,932 | $ 13,941,283 |
Aggregate purchase price |  |  |  |  |  |  | 389 |  |
Seltorexant | Co-Development and License Agreement | Phase 1b Clinical Trials | Maximum |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Share of aggregate development cost following completion of Phase 1b clinical trials and animal toxicology studies |  |  |  | $ 5,000,000 |  |  |  |  |
Seltorexant | Co-Development and License Agreement | Phase 2 Clinical Trials | Maximum |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Share of aggregate development cost following completion of Phase 1b clinical trials and animal toxicology studies |  |  |  | $ 24,000,000 |  |  |  |  |
Janssen | Phase 3 Insomnia Trail |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Milestone method payments |  |  |  |  |  |  | $ 40,000,000 |  |
Percentage of milestone payment on development cost |  |  |  |  |  |  | 40.00% |  |
Janssen | Seltorexant | Co-Development and License Agreement |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Payment of license fee |  |  | $ 22,000,000 |  |  |  |  |  |
Percentage of development costs related to joint development of products |  |  |  | 40.00% |  |  |  |  |
Accrued collaborative expenses |  |  |  |  | 0 |  | $ 0 |  | $ 2,500,000
Payment of development costs |  | $ 3,500,000 |  |  |  |  | 2,500,000 | 0 |
Direct expenses incurred |  | $ 300,000 |  |  |  |  |  |  |
Research and development expense |  |  |  |  | 4,500,000 | $ 3,500,000 | 11,200,000 | $ 3,500,000 |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Upfront payment | $ 30,000,000 |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 41,200,000 |  | $ 41,200,000 |  |
Accrued collaborative expenses | 11,200,000 |  |  |  |  |  |  |  |
Revenue recognition, milestone method, factors |  |  |  |  |  |  | The $30 million payment and $11.2 million in previously accrued collaborative expenses, which were forgiven upon the effective date of the agreement, will be earned and recognized as revenue as the services are performed from the commencement of Phase 3 development to the completion of the development activities using the proportional performance method. |  |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Upfront Payment |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 30,000,000 |  | $ 30,000,000 |  |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Previously Accrued Collaborative Expenses |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 11,200,000 |  | 11,200,000 |  |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Phase 3 Insomnia Trail |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Accrued collaborative expenses | 11,200,000 |  |  |  |  |  |  |  |
Payment start of Phase | 20,000,000 |  |  |  |  |  |  |  |
Payment upon enrollment of patients | $ 20,000,000 |  |  |  |  |  |  |  |
Percentage of patients to be enrolled | 50.00% |  |  |  |  |  |  |  |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Phase 3 Insomnia Trail | Upfront Payment |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | 30,000,000 |  | 30,000,000 |  |
Janssen | Seltorexant | Amendment to Co-Development and License Agreement | Phase 3 Insomnia Trail | Previously Accrued Collaborative Expenses |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  | $ 11,200,000 |  | $ 11,200,000 |  |
Johnson & Johnson Innovation-JJDC Inc |  |  |  |  |  |  |  |  |
Co-development and license agreement |  |  |  |  |  |  |  |  |
Stock repurchased | 3.9 |  |  |  |  |  |  |  |
Stock repurchased price per share | $ 0.0001 |  |  |  |  |  |  |  |
Aggregate purchase price | $ 389 |  |  |  |  |  |  |  |

X
- Definition Accrued research and development costs current. + References No definition available. + Details
Name: | nerv_AccruedResearchAndDevelopmentCostsCurrent
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the aggregate development costs. + References No definition available. + Details
Name: | nerv_AggregateDevelopmentCosts
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Direct expenses incurred, development costs. + References No definition available. + Details
Name: | nerv_DirectExpensesIncurredDevelopmentCosts
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments for development cost. + References No definition available. + Details
Name: | nerv_PaymentsForDevelopmentCost
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the percentage of development costs related to joint development of any products for which the entity is responsible. + References No definition available. + Details
Name: | nerv_PercentageOfDevelopmentCostsRelatedToJointDevelopmentOfProducts
Namespace Prefix: | nerv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of milestone payment on development cost. + References No definition available. + Details
Name: | nerv_PercentageOfMilestonePaymentOnDevelopmentCost
Namespace Prefix: | nerv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of patients to be enrolled. + References No definition available. + Details
Name: | nerv_PercentageOfPatientsToBeEnrolled
Namespace Prefix: | nerv_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product develpoment cost payable. + References No definition available. + Details
Name: | nerv_ProductDevelpomentCostPayable
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Product develpoment cost payable upon enrollment of patients. + References No definition available. + Details
Name: | nerv_ProductDevelpomentCostPayableUponEnrollmentOfPatients
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Revenue recognition milestone method revenue expected. + References No definition available. + Details
Name: | nerv_RevenueRecognitionMilestoneMethodRevenueExpected
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Stock repurchased price per share. + References No definition available. + Details
Name: | nerv_StockRepurchasedPricePerShare
Namespace Prefix: | nerv_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment paid. + References No definition available. + Details
Name: | nerv_UpfrontPaymentPaid
Namespace Prefix: | nerv_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition A description of the factors that the entity considered in determining whether the milestone or milestones are substantive. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodFactors
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_StockRepurchasedDuringPeriodValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductOrServiceAxis=nerv_SeltrorexantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nerv_PhaseOneBClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nerv_PhaseTwoClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=nerv_JanssenPharmaceuticaNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nerv_PhaseThreeClinicalTrialsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=nerv_SeltorexantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nerv_AmendmentToCoDevelopmentAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nerv_PreviouslyAccruedCollaborativeExpensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=nerv_JohnsonAndJohnsonInnovationJJDCIncorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |